Navigation Links
FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
Date:9/23/2008

ndolol, we are taking a major step forward in our quest to bring the benefits of personalized medicine to cardiovascular disease," said Richard B. Brewer, president and chief executive officer of ARCA biopharma. "We look forward to working with the FDA to make bucindolol available to physicians and patients. We are also working with our partner, LabCorp of America, to develop and introduce a companion genetic test."

In the genetic sub-study of the BEST trial, researchers categorized patients into three groups based on receptor genotype: very favorable, favorable and unfavorable. Patients with the very favorable genotype experienced significant improvements in clinical endpoints compared to placebo, including reductions in all cause mortality, all cause mortality or transplant, cardiovascular mortality, heart failure hospitalization, and cardiovascular hospitalization. While the most robust clinical effects occurred in the very favorable genotype group, patients with the favorable genotype also benefited from treatment with bucindolol. Bucindolol also demonstrated clinically significant improvements in ischemic endpoints including reducing the risk of myocardial infarction. Patients with the unfavorable genotype, approximately 10 percent of the study population, did not respond to bucindolol therapy.

About Beta Blockers

The use of beta blockers is the standard of care in patients with heart failure and left ventricular dysfunction, according to clinical practice guidelines of the Heart Failure Society of America (HFSA), the American Heart Association, and the American College of Cardiology. HFSA guidelines state: "Beta-blocker therapy remains a major advance in the treatment of patients with LV systolic dysfunction. Along with ACE inhibitors, this class of drug is now established as routine therapy in patients with LV systolic dysfunction."

About Heart Failure

Heart failure is a chronic and progressive condition in which the heart c
'/>"/>

SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
2. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
3. FDA Accepts Ranexa(R) sNDA and NDA for Filing
4. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
5. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
6. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
7. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
8. FDA Accepts Immucors Response to Warning Letter
9. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
10. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
11. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, ... webcast of a presentation to investors on Tuesday, ... p.m. PDT.  The presentation will include an overview ... To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... materialise. Yet, scientists are making progress in devising ... such approach relies on quantum dotsa kind of ... field. A new study demonstrates that changing the ... with electrical impulses can help better control them. ... used as quantum information units, which would produce ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... N.Y., Dec. 9, 2011 BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX ® ... and Eurasia, today announced the appointment of  George Gould, ... 2011.  Mr. Gould, an attorney, is Principal of George ...
... RESEARCH TRIANGLE PARK, N.C., Dec. 9, 2011  CeNeRx ... commercializing innovative treatments for diseases of the central ... $4.85 million financing.  Existing investors Perseus Soros Biopharmaceutical ... Funds all participated in the financing.  CeNeRx plans ...
... LA CROSSE, Wis., Dec. 8, 2011  Prem Rabindranauth, MD, a ... in La Crosse, Wis., is using an ... to perform heart bypass surgery. To perform MICS, a very ... long cut through the breast bone that is needed with ...
Cached Biology Technology:BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 2BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 3BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 4CeNeRx BioPharma Completes $4.85 Million Financing 2CeNeRx BioPharma Completes $4.85 Million Financing 3Gundersen Lutheran Offers Heart Surgery with Less Pain, Faster Recovery 2
(Date:7/27/2014)... single computer cannot always find the solution a user ... cluster of computers that analyze a massive data set ... history to present you with targeted ads, and how ... movie. But big data is about more than just ... are generating unprecedented quantities of information. That data may ...
(Date:7/25/2014)... The burn scars on this false-color image from the Terra ... this year,s rash of wildfires in Eastern Russia. The ... the green background. The wildfires have broken across the ... Even in this false-color image from the MODIS instrument, ... the fires that continue. Two recent image features noted below ...
(Date:7/25/2014)... Nearly 600 scientists from 25 countries and ... Meeting organized by the Genetics Society of America ... in Seattle. The conference will feature close to ... results on topics including gene expression and regulation, ... technologies, evolution, aging, and a variety of diseases. ...
Breaking Biology News(10 mins):New tools help neuroscientists analyze 'big data' 2New tools help neuroscientists analyze 'big data' 3New tools help neuroscientists analyze 'big data' 4New tools help neuroscientists analyze 'big data' 5Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2
... delay the onset of Alzheimer,s disease, but none are able ... detection the key to Alzheimers patients maintaining a good quality ... a new device developed by the Georgia Institute of Technology ... inexpensive test that could be administered as part of a ...
... experiments was to test a computer algorithms ability to ... and classify them according to different contexts and individual ... 14 Hungarian sheepdogs (Mudi breed) in six different situations: ... were recorded with a tape recorder before being transferred ...
... plant material and burn it. If managed well most of ... by the growing plants, and so have a low impact ... the growing plants could be used to help solve other ... from the Department of Energy and Environment at Chalmers University ...
Cached Biology News:Portable device quickly detects early Alzheimer's 2Portable device quickly detects early Alzheimer's 3Biomass production -- careful planning can bring many benefits 2
... number is a new product number, ... number. If showing no availability yet, ... number (Z71,487-9) or contact customer service ... neck 100 mm, No. of sidearm ...
... a metabolically stable analog of ... uterine stimulant and abortifacient which ... induce labor. It induces luteolysis ... when given as an intramuscular ...
TGase3 (S-20)...
Amodiaquine...
Biology Products: